Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression

Journal of Urology

Volumn 174, Issue 4 II, 2005, Pages 1527-1531

  Pinthus, Jehonathan H ^b   Sheffer, Yuval ^a   Nagler, Arnon ^b   Fridman, Eduard ^b   Mor, Yoram ^b   Genina, Olga ^a   Pines, Mark ^a  

^a VOLCANI CENTER   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Collagen; Nephroblastoma; Proto oncogene protein c met

Indexed keywords

COLLAGEN TYPE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HALOFUGINONE; SCATTER FACTOR RECEPTOR; WT1 PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHILDHOOD CANCER; COLLAGEN SYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MOUSE; NEPHROBLASTOMA; NONHUMAN; NUDE MOUSE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 24944552844     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000179218.16587.d2     Document Type: Conference Paper

References (20)

1. Coppes, M. J. and Pritchard-Jones, K.: Principles of Wilms' tumor biology. Pediatr Urol Oncol, 27: 423, 2000
2. Lee, B. S. and Haber, D. A.: Wilms tumor and the WT1 gene. Exp Cell Res, 264: 74, 2001
3. Alami, J., Williams, B. R. G. and Yeger, H.: Expression and localization of HGF and met in Wilm's tumours. J Pathol, 196: 76, 2002
4. Ghanem, M. A., Van Der Kwast, T. H., Den Hollander, J. C., Sudaryo, M. K., Mathoera, R. B., Van de Heuwel, M. M. et al: Expression and prognostic value of epidermal growth factor receptor, transforming growth factor D, and c-erb B-2 in nephroblastoma. Cancer, 92: 3120, 2001
5. Paulino, A. C., Wen, B. C., Brown, C. K., Tannous, R., Mayr, N. A., Zhen, W. K. et al: Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys, 46: 1239, 2000
6. Abramson, L. P., Grundy, P. E., Rademaker, A. W., Helenowski, I., Cornwell, M., Katzenstein, H. M. et al: Increased microvascular density predicts relapse in Wilms' tumor. J Pediatr Surg, 38: 325, 2003
7. Kalapurakal, J. A., Dome, J. S., Perlman, E. J., Malogolowkin, M., Haase, G. M., Grundy, P. et al: Management of Wilm's tumor: current practice and future goals. Lancet Oncol, 5: 37, 2004
8. Pines, M., Vlodavsky, I. and Nagler, A.: Halofuginone: from veterinary use to human therapy. Drug Develop Res, 50: 371, 2000
9. Pines, M., Snyder, D., Yarkoni, S. and Nagler, A.: Halofuginone to treat fibrosis in chronic graft versus host disease and scleroderma. Biol Bone Marrow Transplant, 9: 417, 2003
10. Rowe, D. H., Huang, J., Kayton, M. L., Thompson, R., Troxel, A., O'Toole, K. M. et al: Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg, 35: 30, 2000
11. Elkin, M., Ariel, I., Miao, H. Q., Nagler, A., Pines, M., de-Groot, N. et al: Inhibition of bladder carcinoma angiogenesis, stromal support and tumor growth by halofuginone. Cancer Res, 59: 4111, 1999
12. Abramovitch, R., Dafni, H., Neeman, M. and Pines, M.: Inhibition of neovascularization, tumor growth and facilitation of wound repair by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia, 1: 321, 1999
13. Gross, D. J., Reibstein, I., Weiss, L., Slavin, S., Dafni, H., Neeman, M. et al: Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res, 9: 3788, 2003
14. Gavish, Z., Pinthus, J. H., Barak, V., Ramon, J., Nagler, A., Eshhar, Z. et al: Growth inhibition of prostate cancer xenografts by halofuginone. Prostate, 51: 73, 2002
15. Pinthus, J. H., Fridman, E., Dekel, B., Goldberg, I., Kaufman-Francis, K., Eshhar, Z. et al: Erb B2 is a tumor-associated antigen and a suitable therapeutic target in Wilms' tumor. J Urol, 172: 1644, 2004
16. Elkin, M., Miao, H. Q., Nagler, A., Aingorn, E., Reich, R., Hemo, I. et al: Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J, 14: 2477, 2000
17. Nagler, A., Ohana, M., Shibolet, O., Shapira, M. Y., Alper, R., Vlodavsky, I. et al: Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Eur J Cancer, 40: 1397, 2004
18. Dey, B. R., Sukhatmem, V. P., Roberts, A. B., Sporn, M. B., Rauscher, F. and J. Kim, S. J.: Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol Endocrinol, 8: 595, 1994
19. McGaha, T. L., Phelps, R. G., Spiera, H. and Bona, C.: Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol, 118: 461, 2002
20. Ding, S., Merkulova-Rainon, T., Han, Z. C. and Tobelem, G.: HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood, 101: 4816, 2003